Pharmaceutical

Magazine: UK’s new Netflix-style funding model for anti...

In this issue: UK’s new Netflix-style funding model for antibiotics, the Swiss b...

Pharma M&A: The top high value deals in 2023

From Pfizer’s Seagen acquisition to Sanofi’s deal with Provention Bio, Pharmaceu...

Medical packaging companies in pharmaceutical contract ...

Discover the critical factors in choosing medical packaging companies for pharma...

Sanofi and Biovac partner to produce polio vaccines in ...

Sanofi and Biovac have announced a partnership to establish the first African-ba...

AstraZeneca’s Truqap and Faslodex combo receives approv...

AstraZeneca has received approval for Truqap in combination with Faslodex in the...

Will WHO’s new guidance spur hepatitis B immunisation?

Based on the updated guidelines, over 50% of individuals with chronic hepatitis ...

EHA 2024: Monoclonal antibodies continue to dominate mu...

Trial investigators anticipate that the FDA will decide on approval for linvosel...

Sarepta’s Elevidys secures US label expansion for DMD

Sarepta’s stock rose by over 36% following the positive news of the FDA expandin...

Tectonic bets on GPCR heart failure drug following reve...

The company has also raised $130.7m in a private placement, which along with Tec...

WHO warns of “harmful” fake Ozempic in circulation in A...

Both Novo Nordisk and Eli Lilly have filed lawsuits against unapproved sellers o...

South Korea seeks to accelerate drug reimbursement admi...

South Korea is moving forward with reforming its national health insurance syste...

Emergent to sell US sterile manufacturing facility to Bora

Emergent BioSolutions has agreed to divest its sterile manufacturing facility in...

Johnson & Johnson seeks FDA approval for Tremfya for Cr...

Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA f...

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Chol...

TYRA-200 is under clinical development by Tyra Biosciences and currently in Phas...

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood o...

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for P...

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarc...

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for B...